title: Different dosages of intravitreal triamcinolone acetonide injections for macular edema secondary to central retinal vein occlusion.
abstract: OBJECTIVE
  To study the effect of intravitreal injections of triamcinolone acetonide (TA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO) in a sample of Chinese patients from Shaanxi province.
  
  
  METHODS
  The 50 eyes from 50 patients were separated into three TA treatment groups: 17 patients were given 4mg /0.1ml, 19 patients were given 8mg /0.2ml, and 14 patients were given 16mg /0.4ml. Patients were followed up for 12 months. Foveal thickness, intraocular pressure (IOP), and best-corrected visual acuity (BCVA) were measured.
  
  
  RESULTS
  Macular edema responded well both anatomically and functionally to the TA injections. After the initial intravitreal injection, macular edema recurred at 2-4 months in the low-dose group (4 mg), at 3-5 months in the medium-dose group (8 mg), and at 6-9 months in the high-dose group (16 mg). No significant difference in BCVA or in foveal thickness were observed between the first intravitreal injection and the re-injection. There was no increase in IOP after re-injection of 16mg TA, if the patient did not have an elevated IOP after the initial intravitreal injection of 4/8 mg TA.
  
  
  CONCLUSIONS
  A low dosage of TA(4 mg) administered via intravitreal injection might be useful as an initial treatment for macular edema secondary to CRVO. A higher dosage of TA (16mg) can be used if there is no IOP elevation with the initial TA injection.
authors.affiliation: Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong University, China. weiyongdoctor@163.com
authors.forename: Yong
authors.initials: Y
authors.lastname: Wei
authors.forename: Huaizhou
authors.initials: H
authors.lastname: Wang
authors.forename: Fenghua
authors.initials: F
authors.lastname: Chen
authors.forename: Zhongqiao
authors.initials: Z
authors.lastname: Zu
authors.forename: Chuncao
authors.initials: C
authors.lastname: Bi
authors.forename: Xinguang
authors.initials: X
authors.lastname: Yang
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012170:Retinal Vein Occlusion; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide